Effect of active immunization with IL‐17A on B cell function and infection risk in pristane‐induced lupus model

Handono, Kusworini; Pratama, Mirza Zaka; Sari, Dita Kartika; Hermawan, Hanestya Oky; Agdana, Hafishtyawan Maulidyananta; Kawuningan, Keryasta Becik; Nur'aini, Nafisah; Hasanah, Dian; Kalim, Handono

doi:10.1111/1756-185x.13325

Cited by 3 publications

(4 citation statements)

References 38 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a major component of humoral immunity, B lymphocytes play a crucial role in the pathogenesis of autoimmune encephalitis. 5 , 37 , 38 Autopsy pathology of patients with anti-NMDAR encephalitis showed that a large number of B cells and CD138+ cells were distributed in the perivascular, interstitial, and perivascular spaces, which provided evidence for the involvement of B cells in immune regulation. 26 B cell-targeting therapies, including RTX, are effective in anti-NMDAR encephalitis, especially in recurrent and severe patients.…”

Section: Discussionmentioning

confidence: 99%

Role of Increased Syncytin-1 Expression in Pathogenesis of Anti-N-Methyl-d-Aspartate Receptor Encephalitis

Qiao¹,

Sun²,

Zhang³

et al. 2022

NDT

View full text Add to dashboard Cite

Purpose Syncytin-1 may play a role in several neuropsychiatric disorders, but its function in anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is unknown. The purpose of this study was to examine the possible mechanism of action of syncytin-1 in patients with anti-NMDAR encephalitis. Patients and Methods Twenty patients with anti-NMDAR encephalitis and eight controls were recruited. The protein levels of syncytin-1 in serum were determined using an enzyme-linked immunosorbent assay, and the transcript levels of syncytin-1 were determined using real-time quantitative PCR. Flow cytometry was used for peripheral blood lymphocyte subset detection. Further, the relationship between syncytin-1 levels and clinical features of anti-NMDAR encephalitis and peripheral blood lymphocyte subsets was analyzed. Results Compared with those in controls, higher syncytin-1 levels and percentage of B cells (CD3-CD19+) were observed in patients with anti-NMDAR encephalitis. Among anti-NMDAR encephalitis patients, the level of syncytin-1 positively correlated with the proportion of B cells and modified Rankin scale score at onset and after immunotherapy and negatively correlated with the proportion of CD3+ T cells. Conclusion An increased expression of Syncytin-1 is associated with the pathogenesis of anti-NMDAR encephalitis, providing evidence for elucidating the pathogenesis of the disease and suggesting novel therapeutic targets. Further, this study clarifies the role of syncytin-1 in neuroimmune disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of Increased Syncytin-1 Expression in Pathogenesis of Anti-N-Methyl-d-Aspartate Receptor Encephalitis

Qiao¹,

Sun²,

Zhang³

et al. 2022

NDT

View full text Add to dashboard Cite

show abstract

“…13 The T helper (T h ) type 17 lymphocytes, that secrete IL-17, and IL-17 itself also have been associated in vitro and in vivo with B cell activation and antibody production, having direct B-cell helper properties. 12,[14][15][16] Several studies have confirmed the importance of IL-17 in the pathogenesis of autoimmune diseases in humans, and specifically AIHA. 11,12,17 In a murine model of AIHA, IL-17-secreting cells were significantly increased in the diseased mice, and targeted treatment that decreased IL-17 concentration decreased the incidence of AIHA.…”

Section: Introductionmentioning

confidence: 93%

“…Interleukin (IL)‐17 is a pro‐inflammatory cytokine involved in recruiting and activating neutrophils, monocytes, and endothelial cells 13 . The T helper (T h ) type 17 lymphocytes, that secrete IL‐17, and IL‐17 itself also have been associated in vitro and in vivo with B cell activation and antibody production, having direct B‐cell helper properties 12,14‐16 . Several studies have confirmed the importance of IL‐17 in the pathogenesis of autoimmune diseases in humans, and specifically AIHA 11,12,17 .…”

Section: Introductionmentioning

confidence: 99%

Serum interleukin 17 concentrations in dogs with immune‐mediated hemolytic anemia

Cuq

Blois

Bédard

et al. 2020

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Increased serum interleukin 17 (IL‐17) concentration has been associated with the immunopathogenesis of autoimmune hemolytic anemia in humans. No data are available about IL‐17 in immune‐mediated hemolytic anemia (IMHA) of dogs. Objectives Monitor changes in serum IL‐17 concentration during the acute stages of IMHA in dogs, compared with results in healthy dogs, and its relationship with outcome. Animals Thirty‐one client‐owned dogs with primary IMHA and 27 healthy dogs. Methods Quantification of serum IL‐17 concentration using a commercially available ELISA kit at the time of admission (D0), after 48 hours (D2) and after 96 hours (D4) as compared to concentration in healthy dogs. The IMHA dogs were classified as survivors if discharged from hospital, or nonsurvivors for any cause of in‐hospital mortality. Results Mean serum IL‐17 concentration was higher in dogs with IMHA on admission compared with healthy dogs (D0), but this difference was not significant (mean, 19.52 pg/mL vs 10.52 pg/mL, respectively, P = .17). Throughout hospitalization, serum IL‐17 concentration significantly decreased in survivors. Serum IL‐17 concentration at D0 was not different between survivors and nonsurvivors, but surviving dogs had significantly lower serum IL‐17 concentration at D2 and D4 (P = .04 and P = .004, respectively) compared with nonsurviving dogs. No correlation was found between serum IL‐17 concentration and serum total bilirubin or lactate concentrations or CBC parameters. Conclusion and Clinical Importance Serum IL‐17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL‐17 concentration a potential biomarker for severity and response to treatment in IMHA.

show abstract

“…Clinical trials showed that IFN-K was well tolerated and significantly reduced disease activity in SLE patients [163,164]. Vaccination therapy by targeting pathogenic cytokines such as IL-17 has also been studied as potential treatments for SLE [161,165,166]. B cell-targeted therapy has been regarded a promising therapeutic approach for SLE, and anti-CD20 monoclonal antibodies such as rituximab have been proven to be effective in SLE patients.…”

Section: Journal Of Immunology Researchmentioning

confidence: 99%

Peptide-Based Vaccination Therapy for Rheumatic Diseases

Wang

Chen

Zheng

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Rheumatic diseases are extremely heterogeneous diseases with substantial risks of morbidity and mortality, and there is a pressing need in developing more safe and cost-effective treatment strategies. Peptide-based vaccination is a highly desirable strategy in treating noninfection diseases, such as cancer and autoimmune diseases, and has gained increasing attentions. This review is aimed at providing a brief overview of the recent advances in peptide-based vaccination therapy for rheumatic diseases. Tremendous efforts have been made to develop effective peptide-based vaccinations against rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), while studies in other rheumatic diseases are still limited. Peptide-based active vaccination against pathogenic cytokines such as TNF-α and interferon-α (IFN-α) is shown to be promising in treating RA or SLE. Moreover, peptide-based tolerogenic vaccinations also have encouraging results in treating RA or SLE. However, most studies available now have been mainly based on animal models, while evidence from clinical studies is still lacking. The translation of these advances from experimental studies into clinical therapy remains impeded by some obstacles such as species difference in immunity, disease heterogeneity, and lack of safe delivery carriers or adjuvants. Nevertheless, advances in high-throughput technology, bioinformatics, and nanotechnology may help overcome these impediments and facilitate the successful development of peptide-based vaccination therapy for rheumatic diseases.

show abstract

Effect of active immunization with IL‐17A on B cell function and infection risk in pristane‐induced lupus model

Abstract: Active immunization with IL-17A coupled to KLH was able to induce a high titer of neutralizing antibodies against IL-17A and inhibit B cell functions without increasing the risk of infection in a pristane-induced lupus mice model.

Cited by 3 publications

References 38 publications

Role of Increased Syncytin-1 Expression in Pathogenesis of Anti-N-Methyl-d-Aspartate Receptor Encephalitis

Role of Increased Syncytin-1 Expression in Pathogenesis of Anti-N-Methyl-d-Aspartate Receptor Encephalitis

Serum interleukin 17 concentrations in dogs with immune‐mediated hemolytic anemia

Peptide-Based Vaccination Therapy for Rheumatic Diseases

Contact Info

Product

Resources

About